Back to All Resources

KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo

October 19, 2022

20th Annual Discovery on Target Conference

View Poster

Area of Focus

Oncology

Programs

STAT3 (KT-333)

Indications

Liquid Tumors Solid Tumors

Development Stage

Pre-clinical Data

Share

You may also be interested in these resources

June 14, 2023

Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors

International Conference on Malignant Lymphoma (ICML) 2023

View Resource

October 19, 2022

KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo

20th Annual Discovery on Target Conference

View Resource

June 1, 2022

Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

View Resource